Congenital hyperinsulinism (CHI) is a rare hormonal disorder characterized by inappropriate insulin secretion in the pancreas resulting in episodes of low blood sugar levels known as hypoglycemia. The major treatment approaches for CHI include diazoxide therapy, octreotide therapy, calcium channel blockers, and surgical procedures. Diazoxide is the first line therapy, but not all patients are responsive to it, in such cases, alternative medical therapies including octreotide, calcium channel blockers and surgical approaches are considered. Surgery is recommended in cases where medical therapy is ineffective.
The global congenital hyperinsulinism treatment market is estimated to be valued at US$ 217.74 Mn in 2023 and is expected to exhibit a CAGR of 6.2% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
The global congenital hyperinsulinism treatment market is driven by increasing awareness about congenital hyperinsulinism and its management. The major key factors contributing to the growth of the market are growing clinical trials evaluating new treatment options and increasing research funding for rare diseases. Furthermore, rising healthcare expenditure and presence of established market players focused on developing newer treatment options are also expected to fuel the market growth over the forecast period. However, low disease prevalence and lack of definitive diagnostic methods can hamper the market growth.
Market key trends:
The key trends in the congenital hyperinsulinism treatment market include increasing preference for precision medicine approach and targeted therapies. Researchers are developing novel targeted treatments delivered through the hepatic arterial route to minimize systemic exposure and side effects. For instance, SiRNA nanotherapy specifically targets genes involved in insulin secretion for long-term management of CHI. Companies are also developing small molecule inhibitors of potassium channels that regulate insulin secretion. These targeted approaches are expected to offer safe and effective treatment alternatives to surgery in the coming years. Furthermore, ongoing clinical research evaluating efficacy of low glycemic index diet and improvement in surgical techniques will further expand treatment options for congenital hyperinsulinism over the forecast period.
Porter’s Analysis
Threat of new entrants: Low barriers to entry as most drugs are off-patent. However, established brands and need for regulatory approvals pose threats.
Bargaining power of buyers: Large number of buyers like hospitals and patients. But rare condition limits bargaining power.
Bargaining power of suppliers: Few suppliers of raw materials and technologies gives them bargaining power. However, several alternative suppliers balance this.
Threat of new substitutes: Limited threat as congenital hyperinsulinism has few substitutes or alternative treatments.
Competitive rivalry: Intense competition between key industry players to gain higher market share.
Key Takeaways
The Global Congenital Hyperinsulinism Treatment Market Size is expected to witness high growth.
Regional analysis: North America is expected to account for the largest share of the congenital hyperinsulinism treatment market during the forecast period. This is attributed to the presence of sophisticated healthcare systems, high healthcare spending, growing awareness about rare diseases, and availability of advanced treatment options.
Key players: Key players operating in the congenital hyperinsulinism treatment market are Medtronic, Ace-medical, VOGT MEDICAL, BD (Becton, Dickinson and Company), Smiths Medical, Inc., Samtronic., CODAN ARGUS AG, B. Braun SE, Medical Components, Inc., Fresenius SE & Co. KGaA, Baxter, EuroLife Healthcare Pvt. Ltd, and Micrel Medical Devices. Medtronic is one of the leading players offering devices for congenital hyperinsulinism like Insulin Pumps.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it